Prolific Machines, a biotechnology firm developing optogenetics-based solutions for protein manufacturing, has been accepted into the FDA’s Emerging Technology Program, the company announced this week. The FDA’s Center for Drug Evaluation and Research (CDER) program supports the adoption of novel manufacturing technologies with the potential to improve drug quality and availability. Prolific’s inclusion in the…